Monte Rosa Therapeutics, Inc. (GLUE)

Market Cap	423.98M
Revenue (ttm)	177.99M
Net Income (ttm)	24.17M
Shares Out	61.76M
EPS (ttm)	0.29
PE Ratio	23.33
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,120,553
Open	6.41
Previous Close	6.36
Day's Range	6.41 - 7.05
52-Week Range	3.50 - 12.40
Beta	1.42
Analysts	Buy
Price Target	13.50 (+96.65%)
Earnings Date	Nov 6, 2025

About GLUE

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 24, 2021
• Employees: 134
• Stock Exchange: NASDAQ
• Ticker Symbol: GLUE
• Website: https://www.monterosatx.com

Analyst Summary

According to 2 analysts, the average rating for GLUE stock is "Buy." The 12-month stock price target is $13.5, which is an increase of 96.65% from the latest price.

Price Target

$13.5

(96.65% upside)

Analyst Consensus: Buy